LONDON (Alliance News) - Scancell Holdings PLC on Thursday said its ImmunoBody technology has been chosen for use in a new preclinical study, to be undertaken by researchers at Nottingham Trent University and the University of Portsmouth.
The preclinical study is aimed at developing a vaccine for the treatment of glioblastoma multiforme, which is the most common and aggressive form of the tumour glioma, Scancell said, noting that current treatments are "limited" and patients have an average survival time of 14 months.
The researchers are aiming to develop a vaccine which stimulates protective immune responses against tumour molecules, such as HAGE or TRP-2, using Scancell's ImmunoBody technology platform. If the cells can become immune to the tumour molecules, it will demonstrate the ability of a patient's immune system to identity and kill the cancer cells.
The GBP95,000 study is being funded by the cancer charity Headcase Cancer Trust, Scancell said.
"We are keen to collaborate on this exciting project to add HAGE to our TRP-2/gp100 vaccine to target glioblastoma multiforme. It is an aggressive disease and we believe the high avidity T cells generated by ImmunoBody will be needed to control its growth," said Chief Scientific Officer Lindy Durrant.
Shares in Scancell were up 2.1% at 20.30 pence on Thursday.
By Hannah Boland; hannahboland@alliancenews.com; @Hannaheboland
Copyright 2016 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)